Essential Amino Acids Supplementation intervention

Phase 2

HeartSciences Inc. (HSCSW)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Metabolic-dysfunction Associated Steatotic Liver Disease

View Full Landscape

Drug Information

Target Indication

Metabolic-dysfunction Associated Steatotic Liver Disease

Clinical Trial

NCT07459504

Last updated: 8/21/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/28/2025

Maapliv

Maapliv is indicated for the treatment of maple syrup urine disease (MSUD) presenting with an acute decompensation episode in patients from birth who are not eligible for an oral and enteral branched-chain amino acids free (BCAA- free) formulation.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

HSCSW

HeartSciences Inc.

Finance Services•North America•NASDAQ

Related Pipeline

Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]Phase 3

Iron-deficiency

Sacubitril-Valsartan 49 Mg-51 Mg Oral TabletPhase 3

Obesity

Mono-Therapy with SildenafilPhase 3

Pediatric Pulmonary Hypertension

Convalescent PlasmaPhase 3

Covid19

FosinoprilPhase 3

Microalbuminuria

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts